A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.

Sutro Biopharma, a US-based cancer drug developer backed by pharmaceutical firms Amgen, Celgene, Eli Lilly and Merck & Co that is based on research at Stanford University, filed for a $75m initial public offering on the Nasdaq Global Market on Wednesday. Founded in 2003 as Fundamental Applied Biology, Sutro Biopharma is creating immuno-onology treatments, antibody…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.